Genetic testing has become an impactful method for clinicians to help their patients confirm their chances of inheriting a genetic disease. Testing quality is an imperative element in determining a patient’s next steps and whether their family members should also be tested.
On November 16th, Ambry CEO Aaron Elliott, PhD and Robina Smith, MD, PhD, Breast Cancer Surgeon and Ambry Director of Medical Affairs, joined breast cancer survivor Christine Fenwick to discuss the importance of utilizing high quality genetic testing, the effects of identifying a patient’s risk for hereditary cancer through family history and how it personally affected Fenwick’s next steps.
Throughout the episode, Fenwick describes her experience in testing positive for the ATM gene and how it impacted her daughter’s decision to also have genetic testing.
Dr. Smith talks about how identifying a patient’s risk for hereditary cancer through family history and the importance of utilizing quality genetic testing has a significant impact on a patient’s diagnosis, including decisions about future treatment for their patient.
While touring through Ambry’s newly built SuperLab, Dr. Elliott discusses Ambry’s big data sharing program, AmbryShare and how it continues to impact the medical research community. It is Ambry's hope that through this program, genes such as ATM can be better understood.
Ambry offers several different types of resources for clinicians and their patients, including a family history questionnaire, which can help determine if someone is at risk for hereditary cancer. For more information about our hereditary cancer patient resources, click here
To access Ambry’s Family History Risk Indicator, click here.
